Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas VP-Business Development Masaki Doi: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)

This article was originally published in The Pink Sheet Daily

Executive Summary

Japanese pharma exec discusses Astellas’ global licensing strategy, the FibroGen deal, and the changing paradigm of Japanese deal flow.

You may also be interested in...



Astellas Sees Further FDA Action On Prograf MR In Early 2008

Astellas responded in July to an "approvable" letter received in January for use of the immunosuppressant Prograf MR (tacrolimus) in liver transplantation, the Japanese pharma revealed during its first quarter 2007 earnings call August 1

Astellas Sees Further FDA Action On Prograf MR In Early 2008

Firm and partner FibroGen also plan response to FDA’s clinical hold on their novel EPO candidates by year end.

Astellas Sees Further FDA Action On Prograf MR In Early 2008

Firm and partner FibroGen also plan response to FDA’s clinical hold on their novel EPO candidates by year end.

Related Content

Topics

UsernamePublicRestriction

Register

PS065865

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel